Minerva神經科學 NERV 深 滬
等待開盤 08-20 09:30:00 美东时间
2.2905
-0.149
-6.13%
華盛通- 最 高2.42
- 今 開2.42
- 成交量 2.14万股
- 最 低 2.27
- 昨 收 2.44
- 總市值 1601.84万
- 52周最高 3.00
- 市盈率 靜 12.06
- 換手率 0.31%
- 52周最低 1.15
- 委 比 90.62%
- 總股本 699.34万
- 歷史最高 126.72
- 量 比 0.16
- 振 幅 6.15%
- 歷史最低 1.15
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Minerva Neurosciences shares are trading higher after the company reported a Q2 EPS beat.
Minerva Neurosciences shares are trading higher after the company reported a Q2...
08-15 04:54
Minerva Neurosciences Q2 EPS $(0.43) Beats $(0.90) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.90) by 52.22 percent. This is a 60.55 percent increase over losses of $(1.09) per share
08-15 04:37
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences announced that the FDA has confirmed the need for an additional confirmatory clinical trial for roluperidone to address deficiencies cited in a previous Complete Response Letter. The trial will focus on patients with schizophrenia experiencing negative symptoms and stable positive symptoms, requiring a double-blind, single-dose regimen with a 12-week primary endpoint assessing changes in negative symptoms. The company also e...
08-14 20:35
Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. announced it will release its second quarter 2025 financial and operating results before market open on August 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be available via webcast and phone. Neuronetics, a leader in neurohealth solutions, specializes in the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for depression and anxiety when traditional medications fail.
07-22 12:30
必胜客×新世纪福音战士：二搭同步率100%味觉补完计划
近日，EVA主题巨型机体装置空降上海、杭州和广州三城必胜客门店，标志性紫色涂装的初号机、红色涂装的2号机以及深度还原的驾驶舱格外醒目，引得路人纷纷驻足打卡...
04-29 20:27
Minerva Neurosciences Reports Improved 2024 Financials
Minerva Neurosciences ( ($NERV) ) has released its Q4 earnings. Here is a break...
03-06 12:14
美股大行评级 | Stifel：维持Agilon Health"持有"评级，目标价从2美元升至3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1101791398596456448.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Prothena Corp(PRTA)"超配"评级，目标价从94美元升至110美元</p> <p>• HC Wainwright & Co.：维持Karyopharm Therape
02-27 11:06
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges
Minerva Neurosciences ( ($NERV) ) has released its Q3 earnings. Here is a break...
2024-11-06 12:34
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $5
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and lowers the price target from $7 to $5.
2024-08-08 04:21
快讯 | Minerva神经科学公司：H.C. Wainwright将目标价从7美元下调至5美元。
Minerva Neurosciences Inc : H.c. Wainwright Cuts Target Price to $5 From $7
2024-08-07 18:11
